SUPPLEMENTAL DATA

Supplemental Table S1. Demographic features of TCGA-LUAD cohort patients

TCGA-LUAD Dataset ($n = 585$)	Male	Female
Patients with Primary Tumor (n=531)	246	287
Patients with Normal Tissue (n=59)	25	34

Supplemental Table S2. Clinical follow-up and gene expression data in the retrospective cohort of patients analyzed at the Department of Oncology, University of Torino, Italy

Patient code	1 st line	PFS	OS	TFEB	ABCC1	ABCA1
	treatment	(months)	(months)	(relative	(relative	(relative
				· · · · · · · · · · · · · · · · · · ·	` 	`
				expression)	expression)	expression)
16-C-00249	ICI-based	18	21	2.13	0.52	2.29
	immunotherapy					
17-C-007826	ICI-based	24	26	2.56	0.41	3.29
	immunotherapy					
17-C-04337	ICI-based	8	5	0.15	2.96	0.21
	immunotherapy					
17-C-04697	ICI-based	12	21	2.58	0.61	1.98
	immunotherapy					
17-C-04914 B	ICI-based	23	26	3.51	0.42	3.15
	immunotherapy					
17-C-05257 A	ICI-based	23	30	3.69	0.28	4.05
	immunotherapy					
17-I-00793A2	ICI-based	21	28	3.01	1.04	3.24
	immunotherapy					
17-I-10155	ICI-based	20	24	2.14	0.62	2.56
	immunotherapy					
17-I-10421	ICI-based	37	46	4.01	0.14	4.5
	immunotherapy					
17-I-12097 B1	ICI-based	35	54	6.12	0.29	4.11
	immunotherapy					
17-I-12406	ICI-based	21	26	2.95	0.61	3.59
	immunotherapy					
17-I-12748	ICI-based	23	23	2.54	0.42	2.93
	immunotherapy					
17-I-13622A2	ICI-based	20	26	3.02	0.69	3.17
	immunotherapy					
17-I-13953 A	ICI-based	18	28	2.04	0.46	2.51
	immunotherapy					
17-I-14050	ICI-based	27	38	3.24	0.84	3.54
	immunotherapy					

18-C-00265	ICI-based	9	19	1.47	0.54	1.97
	immunotherapy					
18-C-01105 B	ICI-based	22	29	2.08	0.59	2.11
	immunotherapy					
18-C-04462	ICI-based	41	53	3.96	0.04	4.96
	immunotherapy					
18-C-04699	ICI-based	8	15	0.42	1.56	0.51
	immunotherapy					
18-C-05582 B	ICI-based	58	71	4.92	0.14	5.36
	immunotherapy					
18-I-00097 B	ICI-based	24	31	2.11	0.39	2.58
	immunotherapy					
18-I-01832	ICI-based	22	27	2.56	0.42	2.14
	immunotherapy					
18-I-02470A2	ICI-based	51	59	4.85	0.18	5.46
	immunotherapy					
18-I-05255	ICI-based	29	50	3.28	0.28	4.02
	immunotherapy					
18-I-05700A2	ICI-based	6	20	1.14	0.14	1.47
	immunotherapy					
18-I-06387 B2	ICI-based	3	9	0.15	2.15	0.26
	immunotherapy					
18-I-07856	ICI-based	14	22	0.81	0.97	1.36
	immunotherapy					
18-I-10670	ICI-based	23	28	0.96	1.13	1.82
	immunotherapy					
18-I-11188	ICI-based	24	45	1.25	0.42	1.98
	immunotherapy					
19-C-01646	ICI-based	35	49	2.28	0.21	2.45
	immunotherapy					
19-C-5330	ICI-based	15	55	3.15	0.17	3.85
	immunotherapy					
19-I-01684	ICI-based	21	30	2.84	0.52	3.24
	immunotherapy					
19-I-08588	ICI-based	4	5	0.08	2.36	0.12
	immunotherapy					

immunotherapy ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1 0.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 1 1 1.8 1.47 1.58 immunotherapy 1 1 1.63 1.23 immunotherapy 1 1 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1 1 1.63 1.23 1.51	19-I-5272 ICI-based 1 2 0.45 3.18 0.39	19-I-5272	ICI-based	1	2	0.45	3.18	0.39
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-023 ICI-based 32 46 3.15 0.18 3.58 20-C-0299 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 11 1.11 1.63 1.23 immunotherapy 2 9 19 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 1.51 1.23 immunotherapy 11 1.11 1.63 1.23 1.51 1.12	immunotherany		immunotherapy					
immunotherapy ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 16 0.09 4.28 immunotherapy 29 63 4.16 0.09 4.28 immunotherapy 1 1 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 1.51 1.12 20-I-2504 ICI-based 43 53 4.5	initiatiouerapy	20-C-02138	ICI-based	11	23	1.91	1.15	2.15
20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 1 1.16 0.19 1.58 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15		immunotherapy					
immunotherapy ICI-based 2 5 0.08 2.89 0.14 20-1-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 20-1-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58 immunotherapy 19 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.11 1.63 1.23 immunotherapy 11 0.81 1.51 1.12 immunotherapy 11 0.81 1.51 1.12 immunotherapy 11 0.81 1.51 1.12 <th>20-C-02138 ICI-based 11 23 1.91 1.15 2.15</th> <th>20-C-2023</th> <th>ICI-based</th> <th>32</th> <th>46</th> <th>3.15</th> <th>0.18</th> <th>3.58</th>	20-C-02138 ICI-based 11 23 1.91 1.15 2.15	20-C-2023	ICI-based	32	46	3.15	0.18	3.58
20-I-00099 ICI-based 2 5 0.08 2.89 0.14 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 9 11 1.11 1.63 1.23 immunotherapy 9 11 0.81 1.51 1.12 immunotherapy 53 4.52 0.05 4.65 immunotherapy 5 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 <t< th=""><th>20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58</th><th></th><th>immunotherapy</th><th></th><th></th><th></th><th></th><th></th></t<>	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58		immunotherapy					
immunotherapy 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58	20-I-00099	ICI-based	2	5	0.08	2.89	0.14
20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 1 1 0.81 1.51 1.12 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14		immunotherapy					
immunotherapy immunotherapy 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 10 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 immunotherapy 10 10 1.51 1.13 immunotherapy 10 11 0.81 1.51 1.12 immunotherapy 11 0.81 1.51 1.12 chemotherapy 11 0.81 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14	20-I-00644 B1	ICI-based	29	63	4.16	0.09	4.28
20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 5 11 0.81 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28		immunotherapy					
immunotherapy ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 1 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 45 62 511 0.17 5.64	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28	20-I-04286	ICI-based	9	19	1.28	1.47	1.58
20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 9 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 Chemotherapy 45 62 511 0.17 564	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 1 2 5 0.08 2.89 0.14 immunotherapy 1 1 29 63 4.16 0.09 4.28 immunotherapy 1 19 1.28 1.47 1.58		immunotherapy					
immunotherapy immunotherapy 43 53 4.52 0.05 4.65 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 45 62 511 0.17 5.64	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 19 1.28 1.47 1.58 immunotherapy 1 19 1.28 1.47 1.58	20-I-2504	ICI-based	9	11	1.11	1.63	1.23
20-I-4408 ICI-based 43 53 4.52 0.05 4.65 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 5 11 0.81 1.51 5.64	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23		immunotherapy					
immunotherapy immunotherapy ITACA 135 Pt-based chemotherapy 5 ITACA 15 Pt based chemotherapy 62	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.6 0.09 4.28 immunotherapy 1 1 1.16 0.09 4.28 immunotherapy 1 1 1.17 1.58 immunotherapy 1 1 1.11 1.63 1.23 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1 1 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23	20-I-4408	ICI-based	43	53	4.52	0.05	4.65
ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 45 62 511 0.17 564	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 2 19 1.28 1.47 1.58 immunotherapy 2 9 11 1.11 1.63 1.23 immunotherapy 2 11 1.11 1.63 1.23 1.47 1.58 immunotherapy 2 11 1.11 1.63 1.23 1.47 1.58 immunotherapy 2 11 1.11 1.63 1.23 <th></th> <th>immunotherapy</th> <th></th> <th></th> <th></th> <th></th> <th></th>		immunotherapy					
chemotherapy ITACA 15 Pt based 45 511 017	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-0203 ICI-based 32 46 3.15 0.18 3.58 20-C-0203 ICI-based 32 46 3.15 0.18 3.58 20-C-0099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 <th>ITACA 135</th> <th>Pt-based</th> <th>5</th> <th>11</th> <th>0.81</th> <th>1.51</th> <th>1.12</th>	ITACA 135	Pt-based	5	11	0.81	1.51	1.12
TTACA 15 Dt based 45 62 511 017 564	Infinituductapy Image: Constraint of the section of the		chemotherapy					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Initiation erapy ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy ICI-based 2 5 0.08 2.89 0.14 immunotherapy ICI-based 2 5 0.08 2.89 0.14 immunotherapy ICI-based 29 63 4.16 0.09 4.28 immunotherapy ICI-based 9 19 1.28 1.47 1.58 immunotherapy ICI-based 9 19 1.28 1.47 1.58 immunotherapy ICI-based 9 11 1.11 1.63 1.23 immunotherapy ICI-based 9 11 1.11 1.63 1.23 immunotherapy ICI-based 43 53 4.52 0.05 4.65 immunotherapy	ITACA 15	Pt-based	45	63	5.11	0.17	5.64
chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 10 20 32 46 3.15 0.18 3.58 immunotherapy 10 20 5 0.08 2.89 0.14 immunotherapy 10 10 2.89 0.14 11 1.15 2.15 20-1-00644 B1 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 10 1.28 1.47 1.58 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 1.23 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 1.23 1.23 1.23 1.23 20-1-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23		chemotherapy					
ITACA 157 Pt-based 4 14 0.76 1.28 0.85	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 1 2 5 0.08 2.89 0.14 immunotherapy 1 1.16 0.9 4.28 1.16 0.09 4.28 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 1 1.11 1.13 1.58 1.47 1.58 immunotherapy 1 1.11 1.11 1.63 1.23 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1.11 1.63 1.23 1.23 1.23 1.23 1.24 1.23 1.23 1.24 1.23 1	ITACA 157	Pt-based	4	14	0.76	1.28	0.85
	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 10 1.11 1.11 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.11 1.63 1.23 immunotherapy 11 0.8		chemotherapy					
chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 1 1.28 1.47 1.58 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-4286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.61 1.23	ITACA 205	Pt-based	1	7	0.38	2.41	0.25
chemotherapy Image: Chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-0203 ICI-based 32 46 3.15 0.18 3.58 20-C-0203 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 0.81 1.51		chemotherapy					
chemotherapy chemotherapy ITACA 205 Pt-based 1 7 0.38 2.41 0.25	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-023 ICI-based 32 46 3.15 0.18 3.58 20-C-023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1.15 2.15 0.08 2.89 0.14 immunotherapy 1 1.16 0.09 4.28 147 1.58 immunotherapy 1 1.28 1.47 1.58 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 20-I-0644 B1 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 1.23 1.45 1.23 1.23 20-I-408 ICI-based 5<	ITACA 206	Pt-based	4	11	0.94	1.48	0.62
chemotherapy Image: Chemotherapy	Immunolectapy Immunole		chemotherapy					
chemotherapychemotherapy0.382.410.25ITACA 205Pt-based170.382.410.25chemotherapy110.941.480.62ITACA 206Pt-based4110.941.480.62	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 1 1 23 0.08 2.89 0.14 immunotherapy 1 1 1 0.18 3.58 1.11 1.15 2.15 20-L00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.6 0.09 4.28 immunotherapy 1 1 1.8 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 immunotherapy 1 1 <t< th=""><th>ITACA 24</th><th>Pt-based</th><th>6</th><th>15</th><th>0.56</th><th>1.52</th><th>0.78</th></t<>	ITACA 24	Pt-based	6	15	0.56	1.52	0.78
chemotherapy Image: Chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2504 ICI-based 53 4.52 0.05 4.65 I		chemotherapy					
chemotherapychemotherapynnnnITACA 205Pt-based170.382.410.25chemotherapy170.941.480.62ITACA 206Pt-based4110.941.480.62chemotherapy1150.561.520.78chemotherapy110.561.520.78	Zo-C-02138 ICI-based 11 23 1.91 1.15 2.15 Zo-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-100099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-100644 B1 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.16 0.09 4.28 immunotherapy 1 1 1.16 0.09 4.28 immunotherapy 1 1 1.63 1.23 1.47 1.58 20-1-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.61 1.23 immunotherapy 1 1 1.11 1.61 1.23 TTAC	ITACA 242	Pt-based	15	16	0.81	1.34	0.72
chemotherapy Image: Chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 inmunotherapy 20-100099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-100644 B1 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1.16 0.09 4.28 1.47 1.58 20-1-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 1 1.28 1.47 1.58 1.47 1.58 20-1-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1.11 1.63 1.23 1.40 1.51 1.12 20-1-4068 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 1 0.81 1.51 1.12 1.12		chemotherapy					
chemotherapychemotherapy170.382.410.25ITACA 205Pt-based170.382.410.25ITACA 206Pt-based4110.941.480.62Chemotherapy1110.941.480.62ITACA 206Pt-based6150.561.520.78ITACA 24Pt-based6150.661.520.78ITACA 242Pt-based15160.811.340.72	Initialization of product of pro	ITACA 244	Pt-based	2	19	1.17	0.91	1.58
chemotherapy ITACA 205 Pt-based 1 7 0.38 2.41 0.25 ITACA 205 Pt-based 1 7 0.38 2.41 0.25 ITACA 206 Pt-based 4 11 0.94 1.48 0.62 ITACA 206 Pt-based 4 11 0.94 1.48 0.62 ITACA 206 Pt-based 6 15 0.56 1.52 0.78 ITACA 24 Pt-based 6 15 0.56 1.52 0.78 ITACA 242 Pt-based 15 16 0.81 1.34 0.72 ITACA 244 Pt-based 2 19 1.17 0.91 1.58	20-C42138 ICI-based 11 23 1.91 1.15 2.15 20-C42138 ICI-based 32 46 3.15 0.18 3.58 20-C4213 ICI-based 32 46 3.15 0.18 3.58 20-C4023 ICI-based 2 5 0.08 2.89 0.14 immunotherapy <td< th=""><th></th><th>chemotherapy</th><th></th><th></th><th></th><th></th><th></th></td<>		chemotherapy					
chemotherapy Image: chemotherapy	20-C-02138 ICL-based 11 23 1.91 1.15 2.15 20-C-2023 ICL-based 32 46 3.15 0.18 3.58 20-C-2023 ICL-based 32 46 3.15 0.18 3.58 20-L00099 ICL-based 2 5 0.08 2.89 0.14 20-L00044 B1 ICL-based 29 63 4.16 0.09 4.28 immunoherapy <	ITACA 292	Pt-based	3	5	0.29	2.25	0.09
ITACA 205 Pt-based 1 7 0.38 2.41 0.25 ITACA 205 Pt-based 1 7 0.38 2.41 0.25 ITACA 206 Pt-based 4 11 0.94 1.48 0.62 ITACA 206 Pt-based 4 11 0.94 1.48 0.62 ITACA 206 Pt-based 6 15 0.56 1.52 0.78 ITACA 24 Pt-based 15 16 0.81 1.34 0.72 ITACA 242 Pt-based 2 19 1.17 0.91 1.58 ITACA 242 Pt-based 2 19 1.17 0.91 1.58 ITACA 242 Pt-based 3 5 0.29 2.25 0.09	20-C42138 ICI-based 11 23 1.91 1.15 2.15 20-C2023 ICI-based 32 46 3.15 0.18 3.58 20-C2023 ICI-based 32 46 3.15 0.18 3.58 20-100099 ICI-based 2 5 0.08 2.89 0.14 20-100644 B1 ICI-based 29 63 4.16 0.09 4.28 immunoherapy <th></th> <th>chemotherapy</th> <th></th> <th></th> <th></th> <th></th> <th></th>		chemotherapy					
chemotherapyI70.382.410.25ITACA 205Pt-based170.382.410.25ITACA 206Pt-based4110.941.480.62chemotherapyITACA 24Pt-based6150.561.520.78ITACA 24Pt-based6150.661.520.78ITACA 242Pt-based15160.811.340.72ITACA 244Pt-based2191.170.911.58chemotherapyITACA 292Pt-based350.292.250.09ITACA 292Pt-based350.292.250.09	Information of product of the product of th			1.4	10	2.15	0.81	1.95
chemotherapy Image: Chemotherapy	20-C-02188 ICL-based 11 23 1.91 1.15 2.15 20-C-2023 ICl-based 32 46 3.15 0.18 3.58 immunotherapy	ITACA 348	Pt-based	14	19	2.15	0.81	1.65
ITACA 15 Pt-based 4.5 0.5 5.11 0.17 5.04 ITACA 157 Pt-based 4 14 0.76 1.28 0.85	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.63 1.23 1.47 1.58 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23	20-I-4408 ITACA 135 ITACA 135 ITACA 15 ITACA 157 ITACA 205 ITACA 206 ITACA 206 ITACA 242 ITACA 242 ITACA 244 ITACA 244	immunotherapyICI-basedimmunotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapyPt-basedchemotherapy	43 5 45 4 1 4 6 15 2 3	53 11 63 14 7 11 15 16 19 5	4.52 0.81 5.11 0.76 0.38 0.94 0.56 0.81 1.17 0.29	0.05 1.51 0.17 1.28 2.41 1.48 1.52 1.34 0.91 2.25	4.65 1.12 5.64 0.85 0.25 0.62 0.78 0.72 1.58 0.09
11ACA 15 11-0aseu 4.5 05 5.11 0.1/ 5.04	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 10 20 5 0.08 2.89 0.14 immunotherapy 10 20 5 0.08 2.89 0.14 immunotherapy 10 29 63 4.16 0.09 4.28 immunotherapy 11 1.18 1.17 1.58 1.17 1.58 immunotherapy 10 128 1.47 1.58 1.23 immunotherapy 11 1.11 1.63 1.23 <t< th=""><th>ITACA 15</th><th>Pt-based</th><th>45</th><th>63</th><th>5.11</th><th>0.17</th><th>5.64</th></t<>	ITACA 15	Pt-based	45	63	5.11	0.17	5.64
TTACA 15 Dt based 45 62 511 017 564	Infinituductapy Image: Second se		chemotherapy					
chemotherapy ITACA 15 Pt based 45 62 511 017 564	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-0203 ICI-based 32 46 3.15 0.18 3.58 20-C-0099 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.63 1.28 1.47 1.58 immunotherapy 1 1 1.16 1.48 1.47 1.58 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 1 1 1 1.63 1.23	ITACA 135	Pt-based	5	11	0.81	1.51	1.12
chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 1 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.61 0.09 4.28 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 1 1.28 1.47 1.58 1.47 1.58 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 1.63 1.23 immunotherapy 1 1 1 1.63 1.23 i	ITACA 135	Pt-based	5	11	0.81	1.51	1.12
ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 45 62 511 0.17 564	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1.63 1.28 1.47 1.58 immunotherapy 1 19 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 20-I-00644 B1 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 1.23 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 1.45 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 1 53 4.52 0.05	YEL GL 425	immunotherapy			0.01		1.10
ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 5 11 0.81 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1 0.19 1.28 0.19 1.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 11 1.11 1.63 1.23 1.23 1.452 0.05 4.65		immunotherapy					
immunotherapy immunotherapy ITACA 135 Pt-based chemotherapy 5 ITACA 15 Pt-based chemotherapy 62	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 2.9 63 4.16 0.09 4.28 immunotherapy 1 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23	20-I-4408	ICI-based	43	53	4.52	0.05	4.65
20-I-4408 ICI-based 43 53 4.52 0.05 4.65 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 5 11 0.81 1.51 5.64	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23		immunotherapy					
immunotherapy immunotherapy 43 53 4.52 0.05 4.65 immunotherapy immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 5 11 0.81 1.51 5.11	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 immunotherapy immunotherapy 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58	20-I-2504	ICI-based	9	11	1.11	1.63	1.23
20-F2304 ICI-based 3 II III IIII IIIII IIIII IIIII IIIII IIIII IIIII IIIIIII IIIIIIIIII IIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 immunotherapy ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy ICI-based 2 5 0.08 2.89 0.14 immunotherapy ICI-based 29 63 4.16 0.09 4.28 immunotherapy ICI-based 9 19 1.28 1.47 1.58	20 1 2504	Immunotherapy	0	11	1 1 1	1.62	1.22
20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 45 62 511 0.17 564	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28	20-I-04286	ICI-based	9	19	1.28	1.47	1.58
20-1-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy ICI-based 9 11 1.11 1.63 1.23 20-1-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 45 63 511 0.17 5.64	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 22 5 0.08 2.89 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 29 63 4.16 0.09 4.28		immunotherapy					
immunotherapy 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 10 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt-based 5 11 0.81 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14	20-I-00644 B1	ICI-based	29	63	4.16	0.09	4.28
20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-2504 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 15 Pt harad 45 62 5 5 5 5	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14		immunotherapy					
immunotherapy immunotherapy 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 10 11 1.11 1.63 1.23 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 chemotherapy 45 62 5 11 0.81 0.17 5	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58	20-I-00099	ICI-based	2	5	0.08	2.89	0.14
20-I-00099 ICI-based 2 5 0.08 2.89 0.14 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 20-I-4408 ICI-based 5 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 <th< th=""><th>20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 315 0.18 358</th><th></th><th>immunotherapy</th><th>52</th><th>10</th><th>5.15</th><th>0.10</th><th>5.50</th></th<>	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 315 0.18 358		immunotherapy	52	10	5.15	0.10	5.50
20-1-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58 immunotherapy 10 1.11 1.63 1.23 immunotherapy 20-1-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 1.11 1.63 1.23 immunotherapy 20-1-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 11 0.81 1.51 1.12 immunotherapy 10 10 0.81 1.51 1.12 immunotherapy 11 0.81 1.51 1.12 immunotherapy 11 0.81 1.51 <	20-C-02138 ICI-based 11 23 1.91 1.15 2.15	20-C-2023	ICI-based	32	46	3.15	0.18	3.58
20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 1 0.19 1 1 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 0.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 1 1.28 1.47 1.58 immunotherapy 1 1.11 1.63 1.23 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 <t< th=""><th></th><th>20-C-02138</th><th>ICI-based</th><th>11</th><th>23</th><th>1.91</th><th>1.15</th><th>2.15</th></t<>		20-C-02138	ICI-based	11	23	1.91	1.15	2.15
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 10 2 5 0.08 2.89 0.14 immunotherapy 11 2 5 0.08 2.89 0.14 immunotherapy 11 1.16 0.09 4.28 0.14 immunotherapy 29 63 4.16 0.09 4.28 inmunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.81 <td< th=""><th>immunotherapy</th><th><u> 20 C 02120</u></th><th>immunotherapy</th><th>11</th><th>22</th><th>1.01</th><th>1.15</th><th>2.15</th></td<>	immunotherapy	<u> 20 C 02120</u>	immunotherapy	11	22	1.01	1.15	2.15
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1.16 0.09 4.28 0.14 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.81 1.51 1.12	1mmunotherany		immunotherapy					
immunotherapy ICI-based 2 5 0.08 2.89 0.14 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy ICI-based 9 19 1.28 1.47 1.58 immunotherapy ICI-based 9 11 1.11 1.63 1.23 immunotherapy ICI-based 9 11 1.11 1.63 1.23 immunotherapy ICI-based 9 11 1.11 1.63 1.23 immunotherapy ICI-based 43 53 4.52 0.05 4.65 immunotherapy ICI-based 5 11 0.81 1.51 1.12 ichemotherapy ICI-based 5 11 0.81 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 immunotherapy 20	20-C-2023	ICI-based	32	46	3.15	0.18	3.58
20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 1 1.11 1.63 1.23 1.23 1.12 immunotherapy 1 1 1.11 1.63 1.23 1.24 1.51 1.12 immunotherapy 1 1 1 1.51 1.12 1.12 1.12 immunotherapy 1 5 11 0.81 <	20-C-02138 ICI-based 11 23 1.91 1.15 2.15		immunotherapy					
immunotherapy immunotherapy 1000000000000000000000000000000000000	minunourerapy	20-C-02138	ICI-based	11	23	1.91	1.15	2.15
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1.16 0.09 4.28 0.14 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.81 1.51 1.12	immunotherany		immunotherapy					
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-4408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 20-I-4408 ICI-based 5 11 0.81 1.51 1.12 immunother	immunotherany		immunotherapy					
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 20-I-4408 ICI-based 5 11 0.81 1.51	immunotherspy		immunotherapy					
Immunotherapy ICI-based 2 5 0.08 2.89 0.14 Immunotherapy ICI-based 2 5 0.08 2.89 0.14 Immunotherapy ICI-based 29 63 4.16 0.09 4.28 Immunotherapy ICI-based 29 63 4.16 0.09 4.28 Immunotherapy ICI-based 9 19 1.28 1.47 1.58 Immunotherapy ICI-based 9 11 1.11 1.63 1.23 Immunotherapy ICI-based 9 11 1.11 1.63 1.23 ICI-based 9 11 1.11 1.63 1.23 Immunotherapy ICI-based 43 53 4.52 0.05 4.65 ITACA 135 Pt-based 5 11 0.81 1.51 1.12 ITACA 135 Pt-based 5 11 0.81 1.51 1.12	20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58							
immunotherapy ICI-based 2 5 0.08 2.89 0.14 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58 immunotherapy 19 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.81 1.51 1.12 immunotherapy 11 0.81 1.51 1.12 immunotherapy 11 0.81 1	20-C-02138 ICI-based 11 23 1.91 1.15 2.15	20-C-2023	ICI-based	32	46	3.15	0.18	3.58
20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 10 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 11 1.11 1.63 1.23 1.23 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 1.11 1.63 1.23 immunotherapy 11 0.81 1.51 1.12 immunotherapy 1 11 0.81 1.51 1.12 chemotherapy	20-C-02138 ICI-based 11 23 1.91 1.15 2.15		immunotherapy					
20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 1 1 0.09 4.28 0.14 immunotherapy 2 5 0.08 2.89 0.14 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 2 63 4.16 0.09 4.28 immunotherapy 1 1 1.8 1.47 1.58 immunotherapy 1 1 1.11 1.63 1.23 immunotherapy 1 1 1 1.11 1.12		20-C-02138	ICI-based	11	23	1.91	1.15	2.15
20-C-02138 ICI-based 11 23 1.91 1.15 2.15 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 20-I-00644 B1 ICI-based 9 19 1.28 1.47 1.58 immunotherapy 20-I-04286 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 10 1.11 1.63 1.23 1.51 1.12 20-I-2504 ICI-based 43	immunotherany		immunotherapy					
immunoherapy ICI-based 11 23 1.91 1.15 2.15 20-C-02138 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 20-C-2023 ICI-based 32 46 3.15 0.18 3.58 immunotherapy 20-I-00099 ICI-based 2 5 0.08 2.89 0.14 immunotherapy 20-I-00644 B1 ICI-based 29 63 4.16 0.09 4.28 immunotherapy 19 1.28 1.47 1.58 20-I-04286 ICI-based 9 19 1.28 1.47 1.58 20-I-2504 ICI-based 9 11 1.11 1.63 1.23 immunotherapy 20-I-2408 ICI-based 43 53 4.52 0.05 4.65 immunotherapy 20-I-4408 ICI-based 5 11 0.81 1.51 1.12	19-I-5272 ICI-based 1 2 0.45 3.18 0.39	19-I-5272	ICI-based	1	2	0.45	3.18	0.39

ITACA 383	Pt-based	1	2	0.17	3.26	0.23
	chemotherapy					
ITACA 426	Pt-based	1	3	0.26	3.82	0.07
	chemotherapy					
ITACA 446	Pt-based	1	6	0.11	2.81	0.19
	chemotherapy					
ITACA 544	Pt-based	2	3	0.18	3.45	0.08
	chemotherapy					
ITACA 587	Pt-based	29	45	3.69	0.15	4.28
	chemotherapy					
ITACA 607	Pt-based	1	2	0.48	4.11	0.19
	chemotherapy					
ITACA 623	Pt-based	12	30	2.54	1.25	3.15
	chemotherapy					
ITACA 624	Pt-based	1	3	0.23	0.46	0.42
	chemotherapy					
ITACA 631	Pt-based	2	5	0.28	0.28	0.53
	chemotherapy					
ITACA 641	Pt-based	29	41	3.46	0.21	3.78
	chemotherapy					
ITACA 670	Pt-based	8	23	2.07	1.14	2.14
	chemotherapy					
ITACA 671	Pt-based	2	6	0.31	2.58	0.32
	chemotherapy					
ITACA 690	Pt-based	3	6	0.46	2.46	0.25
	chemotherapy					
ITACA 715	Pt-based	47	130	5.28	0.09	6.12
	chemotherapy					
ITACA 745	Pt-based	3	11	0.72	1.34	0.81
	chemotherapy					
ITACA 757	Pt-based	30	33	2.16	1.22	2.98
	chemotherapy					
ITACA 759	Pt-based	27	40	3.59	0.32	4.15
	chemotherapy					
ITACA 87	Pt-based	1	6	0.14	2.15	0.22
	chemotherapy					
1	1	1		1		1

ITACA166	Pt-based chemotherapy	22	32	2.19	0.76	2.76
ITACA301	Pt-based chemotherapy	15	28	2.04	0.92	2.15
ITACA636	Pt-based chemotherapy	14	16	1.92	0.72	1.15
MOLEC. 1	ICI-based immunotherapy	2	4	0.41	3.15	0.36
MOLEC. 2	ICI-based immunotherapy	9	17	1.12	1.08	1.24
SI ITACA	Pt-based chemotherapy	21	33	2.73	0.78	2.84

Pt: cisplatin or carboplatin; ICI: immune checkpoint inhibitors; PFS: progression free survival; OS: overall survival. *TFEB*, *ABCA1* and *ABCC1* levels were expressed as relative expression toward the housekeeping gene *B2M*.

During and	Farmand	Derrora
Primers	Forward	Keverse
TFEB	5'-GACTCAGAAGCGAGAGCTAACA	5'-TGTGATTGTCTTTCTTCTGCCG
ABCA1	5'-CAGAGCTCACAGCAGGGAC	5'-CTTCTCCGGAAGGCTTGTC
ABCC1	5' -TCTGGTCAGCCCAACTCTCT	5'-CCTGTGATCCACCAGAAGGT
ATP7B	5'-TCTCTGGTCATCCTGGTGGTT-3'	5'-GGGCTTCTGAGGTTTTGCTCT-3'
B2M	- 5'	5'-
	AGCAAGGACIGGICIIICIAICIC	AIOICICCAICCACITAAGIAICI
		Т
TFEB sites on the		
promoter of		
ARCAI	GGACCCTAAGACACCTGCTG	TTCCCCCCCTCTCTTTATCT
ADCAI	UUACCEIAAUACACEIUCIU	
ABCC1	ACCTCAGTTTCCCCATCTGT	AAGAAACCCAGGTGCAGAGA

Supplemental Table S3. Primer sequences used in qRT-PCR and ChIP

Supplemental Table S4. Cholesterol homeostasis-related genes analyzed by PCR Array

in wild-type and TFEB-silenced cells

NCI-H2228 cells:

Target	WT Normalized	shTFEB Normalized	shTFEB	Compared to Regulation
	Expression	Expression	fold	Threshold
			change	
ABCA1	0.00632	0.00552	-1.14395	No change
ABCG1	0.0382	0.01617	-2.36338	Down-regulated*
ACAA2	0.04657	0.01143	-4.07516	Down-regulated**
ACTB	5.19942	2.66482	-1.95114	Down-regulated*
ANKRA2	0.05191	0.0452	-1.14843	No change
APOD	0.01544	0.01036	-1.48958	No change
APOE	0.00049	0.00008	-5.81657	Down-regulated**
APOL1	0.02616	0.01122	-2.33151	Down-regulated*
APOL2	0.028	0.00999	-2.80211	Down-regulated*
CNBP	0.27238	0.26009	-1.04726	No change
CXCL16	0.05064	0.03065	-1.65227	Down-regulated*
CYB5R3	0.06758	0.01504	-4.49319	Down-regulated*
CYP39A1	0.00102	0.00124	1.21801	No change
CYP51A1	0.03726	0.06578	1.76542	Up-regulated*
DHCR24	0.0476	0.01658	-2.87171	Down-regulated*
DHCR7	0.0146	0.0033	-4.42772	Down-regulated**
FDFT1	0.0315	0.00065	-48.40565	Down-regulated***
FDPS	0.38113	0.20606	-1.84955	Down-regulated*
GUSB	0.22555	0.11849	-1.90363	Down-regulated*
HDLBP	0.45042	0.28273	-1.59308	Down-regulated*
HMGCR	0.00263	0.00177	-1.48091	No change
HMGCS1	0.00454	0.01664	3.66876	Up-regulated**
IDI1	0.04883	0.0637	1.30451	No change
INSIG1	0.09391	0.0647	-1.45142	No change
INSIG2	0.02382	0.04048	1.69928	Up-regulated*
LCAT	0.00172	0.00024	-7.26568	Down-regulated**
LDLR	0.03474	0.03437	-1.0107	No change
LDLRAP	0.01569	0.0065	-2.41377	Down-regulated*
1				

LIPE	0.00531	0.0026	-2.04656	Down-regulated*
LRP10	0.02839	0.01523	-1.86392	Down-regulated*
LRP12	0.01871	0.01645	-1.13739	No change
LRP6	0.01205	0.01351	1.12065	No change
LRPAP1	0.0705	0.04844	-1.45529	No change
MBTPS1	0.11263	0.04245	-2.65347	Down-regulated*
MVD	0.00397	0.00098	-4.03232	Down-regulated**
NR1H4	0.00464	0.00129	-3.59611	Down-regulated**
NSDHL	0.06324	0.04451	-1.42061	No change
OSBPL1A	0.00946	0.01184	1.25146	No change
OSBPL5	0.00508	0.00028	-17.95912	Down-regulated***
PCSK9	0.002	0.00113	-1.76333	Down-regulated*
PMVK	0.05994	0.03129	-1.91548	Down-regulated*
PPARD	0.01303	0.00343	-3.7973	Down-regulated**
PRKAA2	0.00265	0.00639	2.40644	Up-regulated**
PRKAG2	0.06931	0.05961	-1.16277	No change
RPLP0	2.69508	2.21951	-1.21427	No change
SCAP	0.02359	0.00826	-2.85598	Down-regulated**
SCARF1	0.00003	0.0003	10.36432	Up-regulated***
SNX17	0.22834	0.07601	-3.00394	Down-regulated**
SOAT1	0.02597	0.00666	-3.90041	Down-regulated**
SORL1	0.01369	0.00885	-1.54709	No change
SREBF1	0.02128	0.01043	-2.04095	Down-regulated*
SREBF2	0.01569	0.00878	-1.78666	Down-regulated*
STARD3	0.02747	0.01865	-1.47259	No change
TM7SF2	0.29261	0.22981	-1.27327	No change
TRERF1	0.00745	0.00321	-2.32198	Down-regulated*
VLDLR	0.01075	0.0071	-1.51412	No change
		1		

NCI-H441 cells

Target	WT Normalized	shTFEB Normalized	shTFEB	Compared to Regulation
	Expression	Expression	fold	Threshold
			change	
ABCA1	0.01331	0.0287	2.15663	Up-regulated*
ABCG1	0.04606	0.00103	-44.60911	Down-regulated***
ACAA2	0.00234	0.00387	1.65344	No change

ACTB	2.4819	1.88008	-1.3201	No change
AKR1D1	0.0028	0.00203	-1.3773	No change
ANKRA2	0.15805	0.13815	-1.14404	No change
APOA2	0.00593	0.00009	-65.0202	Down-regulated***
APOA4	0.00015	0.0003	2.02819	Up-regulated*
APOD	0.00084	0.00071	-1.18445	No change
APOE	0.00027	0.00011	-2.43598	Down-regulated**
APOF	0.00133	0.00002	-81.02505	Down regulated***
APOL1	0.03516	0.01608	-2.18581	Down-regulated**
APOL2	0.01202	0.00813	-1.47862	No change
CDH13	0.00431	0.00096	-4.48992	Down-regulated**
CELA3B	0.00005	0.00002	-2.2615	Down-regulated**
CNBP	2.09116	2.49292	1.19212	No change
CXCL16	0.02099	0.03593	1.71165	Up-regulated*
CYB5R3	0.037	0.02927	-1.26422	No change
CYP11A1	0.00121	0.00037	-3.27162	Down-regulated**
CYP39A1	0.00335	0.00381	1.13462	No change
CYP51A1	0.19914	0.27185	1.36516	No change
CYP7B1	0.00626	0.00777	1.24155	No change
DHCR24	0.16111	0.17103	1.0616	No change
DHCR7	0.17051	0.13457	-1.26706	No change
FDFT1	0.07277	0.20263	2.78455	Up-regulated**
FDPS	0.83331	0.53098	-1.56938	No change
GUSB	0.21435	0.15087	-1.42079	No change
HDLBP	0.85871	0.63182	-1.35911	No change
HMGCR	0.04428	0.066	1.49064	No change
HMGCS1	0.02989	0.18492	6.18569	Up-regulated**
IDI1	0.38176	0.30556	-1.24936	No change
INSIG1	0.5445	0.46502	-1.17092	No change
INSIG2	0.49204	0.29921	-1.64447	No change
LCAT	0.03399	0.00167	-20.40966	Down-regulated***
LDLR	0.16837	0.22662	1.34596	No change
LDLRAP	0.02131	0.00986	-2.16103	Down-regulated**
1				
LIPE	0.00122	0.00104	-1.1796	No change
LRP10	0.04788	0.02033	-2.35542	Down-regulated**

LRP12	0.11268	0.18731	1.66228	Up-regulated*
LRP6	0.08824	0.13293	1.50646	No change
LRPAP1	0.12919	0.14528	1.12456	No change
MBTPS1	0.25246	0.48357	1.91545	Up-regulated*
MVD	0.0066	0.00492	-1.34042	No change
MVK	0.28939	0.07591	-3.81244	Down-regulated**
NSDHL	0.16373	0.15855	-1.03262	No change
OLR1	0.0077	0.00091	-8.44545	Down-regulated***
OSBPL1A	0.04573	0.05616	1.228	No change
OSBPL5	0.01562	0.00077	-20.31702	Down-regulated***
PCR	0.99884	0.75653	-1.3203	No change
PCSK9	0.01624	0.00053	-30.69018	Down-regulated***
PMVK	0.07279	0.05979	-1.21732	No change
PPARD	0.11381	0.12951	1.13787	No change
PRKAG2	0.2307	0.13982	-1.64997	Down-regulated*
RPLP0	16.7169	0.45742	-36.54624	Down-regulated***
SCAP	0.01359	0.00696	-1.95202	Down-regulated*
SCARF1	0.00268	0.00085	-3.13359	Down-regulated**
SNX17	0.14996	0.20833	1.38928	No change
SOAT1	0.07254	0.16556	2.28219	Up-regulated*
SORL1	0.13875	0.20359	1.46739	No change
SREBF1	0.02541	0.03085	1.21439	No change
SREBF2	0.027	0.02399	-1.12553	No change
STAB1	0.01193	0.00053	-22.64322	Down-regulated***
STARD3	0.03829	0.01876	-2.04119	Down-regulated*
TM7SF2	0.57316	0.43579	-1.31522	No change
TRERF1	0.00132	0.00105	-1.25936	No change
VLDLR	0.00851	0.01108	1.30163	No change

Fold-Change (2⁽⁻Delta Delta Ct)) is the normalized gene expression (2⁽⁻Delta Ct)) in TFEB-silenced (shTFEB) cells, divided the normalized gene expression (2⁽⁻Delta Ct)) in wild-type (WT) cells, where Ct is the threshold cycle in qRT-PCR. Fold-change values greater than 1 indicate up-regulation, fold-change values less than 1 indicate down-regulation. The p values are calculated based on a Student's t-test of the replicate 2⁽⁻Delta Ct)</sup> values for each gene. *p<0.05, *p<0.01, ***p<0.001: shTFEB vs WT cells.

	WT				shTFEB			
	vehicle	РТ	NZ	NZ+PT	vehicle	РТ	NZ	NZ+PT
	venicie		112	112111	venicie		112	112111
RBC	13.23 +	12.18 +	13.21 +	12.18 +	12.59 +	11.29 +	13.48 +	
(x 10 ⁶ /µl)	2.01	1.95	1.42	1.69	2.47	2.61	4.52	12.11 + 3.51
	13.11 +	12.45 +	13.48 +	12.41 +	12.63 +	12.01 +	12.54 +	
Hb (g/dl)	1.44	2.31	0.91	1.13	1.94	2.15	1.59	12.04 + 2.51
WBC	13.28 +	14.37 +	12.04 +	13.08 +	11.07 +	13.29 +	12.11 +	
(x 10 ³ /µl)	3.02	2.39	2.15	1.57	2.07	2.51	1.27	13.45 + 2.45
PLT (x 10 ³ /µl)	873 + 134	745 + 234	916 + 115	8566 + 152	896 + 205	792 + 184	809 + 152	701 + 172
		10523 +						
LDH (U/I)	9823 + 548	627	8912 + 604	7598 + 501	7984 + 412	8216 + 285	7452 + 205	7205 + 236
AST (U/I)	156 + 44	135+34	143 + 39	144 + 49	134+ 29	146 + 34	152 + 47	162 + 44
ALT (U/I)	36 + 14	45 + 11	45 + 19	54 + 23	44 + 18	37 + 11	49 + 15	53 + 11
AP (U/l)	114 + 22	127 + 28	129 + 342	113 + 205	128 + 33	108 + 27	119 + 37	109 + 48
Creatinine	0.071 +	0.082 +	0.069 +	0.079 +	0.074 +	0.079 +	0.072 +	0.0692 +
(mg/l)	0.009	0.007	0.011	0.009	0.007	0.010	0.008	0.011
CPK (U/l)	231 + 22	256 + 42	282+48	304 + 55	205 + 38	249 + 52	281 + 61	298 + 84

Supplemental Table S5. Hematochemical parameters of animals after euthanasia.

Hematochemical parameters measured immediately after mice euthanasia. RBC: red blood cells; WBC: white blood cells; Hb: hemoglobin (Hb); PLT: platelets; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; AP: alkaline phosphatase; CPK: creatine phosphokinase (CPK). Data are means \pm SD (n= 5 mice/group treatment).

Supplemental Figure S1



Supplemental Figure 1. Impact of the expression of TFEB, ABCA1 and ABCC1 on survival of NSCLC patients. Kaplan Meyer analysis of progression-free survival (PFS) and overall survival (OS) in patients treated with cisplatin/carboplatin (Pt; n=32; panel A) or pembrolizumab as immune checkpoint inhibitor (ICI; n=43; panel B) at the Department of Oncology, University of Torino, Italy. Patients were categorized in "high" and low" according to the median levels of TFEB, ABCA1 and ABCC1.



Supplemental Figure S2. TFEB does not affect ubiquitination or phosphorylation of ABC transporters. Ubiquitination (A-B) and phosphorylation (C-D) of ABCA1 (A, C) and ABCC1 (B, D) in wild-type (WT) and TFEB silenced (sh) NCI-H441 and NCI-H2228 cells. Lysates were immunoprecipitated (IP) with an anti-poly-ubiquitination (UQ) or an anti-phosphoserine (pSer) antibody, then immunoblotted (IB) for ABCA1 or ABCC1 (n=3 independent experiments).



-0.6 H441 H2228 shTFEB

Supplemental Figure S3. Analysis of lysosomes, ABCA1, ABCC1 and ATP7B in non-small cell lung cancer cells

(A). Wild-type (WT) and TFEB-silenced (shTFEB) NCI-H2228 cells were stained with the BioTrackerTM 560 Orange Lysosome Dye to label lysosomes plus an anti-ABCA1 or anti-ABCC1 antibody, followed by the DyLightTM 488- or Alexa Fluor488-conjugated secondary antibody. Nuclei were counterstained with DAPI. For each experimental point, a minimum of five microscopic fields were examined. Objective: $63 \times (1.4 \text{ numerical aperture})$; ocular: $10 \times$. Bar=100 µm. (B). ATP7B mRNA in WT NCI-H441 and NCI-H2228 cells, transduced with the pLKO empty vector, and in cells silenced for TFEB (shTFEB), measured by qRT-PCR in triplicates. Data are means±SD of the mRNA fold change (n=3 independent experiments). **p<0.01: shTFEB versus WT cells.



Supplemental Figure S4. Co-immunoprecipitation between SREBP2 and phospho(Thr202/Tyr204)-ERK1/2 in non-small cell lung cancer cells

Lysates from wild-type (WT) and TFEB-silenced (shTFEB) NCI-H2228 cells were immunoprecipitated (IP) for SREBP2, using an antibody recognizing both precursor and cleaved/active SREBP2, then immunoblotted (IB) for phospho(Thr202/Tyr204)-ERK1/2 (n=3 independent experiments). The density of phospho(Thr202/Tyr204)-ERK1/2 in shTFEB cells is indicated below the image, setting the band density of WT cells as 1.



Supplemental Figure S5. Intratumor levels of TFEB after silencing or overexpression. 1×10^6 NCI-H2228 wild-type (WT), TFEB-silenced (shTFEB) cells or shTFEB cells overexpressing TFEBS142A (ovTFEB), mixed with 100 µL Matrigel (Merck), were injected subcutaneously in female NOD SCID- γ (NSG) mice engrafted with human hematopoietic CD34⁺ cells (Hu-CD34⁺). When tumors reached the volume of 50 mm3, animals (n=5/group) were randomized and treated for 3 weeks as it follows: 1) control (CTRL) group, treated with 0.1 ml saline solution intravenously (i.v.), once a week; 2) cisplatin (PT) group, treated with 2 mg/kg cisplatin i.v., once a week. Animals were euthanized on day 28 after randomization with zolazepam (0.2 mL/kg) and xylazine (16mg/kg). RNA was extracted from fresh tumors and analyzed for TFEB expression by qRT-PCR, in triplicates (n=5 animals/group of treatment). Data are means±SD. *p<0.05, ***p<0.001: shTFEB/ovTFEB versus WT tumors; ^{ooo}p<0.001: ovTFEB vs shTFEB tumors.



CTRL NZ

Supplemental Figure S6. Chemo-immuno-sensitizing effects of self-assembled zoledronic acid nanoparticles on TFEB-silenced non-small cell lung cells. Wild-type (WT) or TFEBsilenced (shTFEB) NCI-H2228 cells were incubated 24 h in fresh medium (CTRL) or with 100 nM self-assembled zoledronic acid nanoparticles (NZ). When indicated, 100 µM cisplatin (corresponding to the IC₂₅ in WT cells; PT) was added, alone or with NZ. (A-C) Cholesterol synthesis, IPP synthesis and IPP efflux, measured by metabolic radiolabelling in duplicates. Data are means ± SD (n=3 independent experiments). *p<0.05, **p<0.01, ****p<0.0001: shTFEB cells versus WT cells. (D-E). Expansion and activation of Vy9V82 T-lymphocytes, Vy9V82 T-lymphocyte-mediated NSCLC cell immune-killing, measured by flow cytometry in duplicates. Data are means±SD (n=3 independent experiments). *p<0.05; **p<0.01; ***p<0001, ****p<0.0001: shTFEB versus WT cells. (F-H) Mitochondrial cholesterol and electron transport chain, measured spectrophotometrically in duplicates, mitochondrial (mt) ATP, measured by a chemiluminescence-based assay in duplicates. Data are means \pm SD (n=3 independent experiments). **p<0.01, ***p<0.001, ****p<0.0001: shTFEB versus WT cells. (I-J). ABCC1 catalytic activity, measured spectrophotometrically, and intracellular retention of $[^{14}C]$ -Carboplatin, measured by cell radiolabelling, in duplicates. Data are means \pm SD (n=3) independent experiments). *p<0.05, **p<0.01, ***p<0.001: shTFEB versus WT cells.



Supplemental Figure S7. TFEB levels in explanted tumors. 1×10^6 NCI-H2228 wild-type (WT) and TFEB-silenced (shTFEB) cells were injected subcutaneously in Hu-CD34⁺ mice. When tumors reached the volume of 50 mm³, animals (n=5/group) were randomized and treated for 3 weeks as it follows: 1) control (CTRL) group, treated with 0.1 ml saline solution intravenously (i.v.), once a week; 2) cisplatin (PT) group, treated with 2 mg/kg cisplatin i.v., once a week; 3) NZ, treated with 1 mg/kg NZ i.v., once a week; 4) NZ+PT group, receiving both drugs i.v., once a week simultaneously. Animals were euthanized on day 28 after randomization with zolazepam (0.2 mL/kg) and xylazine (16mg/kg). RNA was extracted from fresh tumors and analyzed for TFEB expression by RT-PCR, in triplicates (n=5 animals/group of treatment). Data are means \pm SD. ****p<0.0001: shTFEB versus WT tumors.



Supplemental Figure S8. Hematoxylin-eosin staining of heart, liver, lung, kidneys, and spleen collected *post-mortem*. The organs were collected from animals of each treatment group immediately after euthanasia, fixed and stained with hematoxylin-eosin. A minimum of 5 field/organ was analyzed in each animal. Objective: 10X; ocular: 10X; Bar =100 μ m.



Supplemental Figure S9. Gene network of biological processes differentially up-regulated in wild-type versus TFEB-silenced non-small cell lung cancer tumors. GSEA performed on clustered cancer cells from wild-type (WT) of TFEB-silenced (shTFEB) tumors in animals treated with vehicle (CTRL; n=2 tumors/group). Purple nodes: significantly regulated processes.



Supplemental Figure S10. Differences in immune-related processes and immune-infiltrating populations in cisplatin-treated non-small cell lung cancers. (A-B). Gene network of biological processes differentially up-regulated in wild-type (WT) versus TFEB silenced (shTFEB) non-small cell lung cancer tumors, based on GSEA performed on clustered cancer cells from animals treated with cisplatin (PT). Purple nodes: significantly regulated processes. (C-D). Quantitative changes, expressed as fold change in a logarithmic scale, of the differentially present immune-infiltrating populations emerged by the comparisons of the following groups: WT PT versus WT CTRL (C), shTFEB PT versus shTFEB CTRL (D; n=2 tumors/group).



Supplemental Figure S11. Differences in immune-related processes and immuneinfiltrating populations in non-small cell lung cancer treated with cisplatin and zoledronic acid. (A-B). Gene network of biological processes differentially regulated in wild-type (WT) versus TFEB silenced (shTFEB) non-small cell lung cancer tumors, based on GSEA performed on clustered cancer cells from animals treated with NZ+PT. Purple nodes: significantly regulated processes. (C-D). Quantitative changes, expressed as fold change in a logarithmic scale, of the differentially present immune-infiltrating populations emerged by the comparisons of the following groups: WT NZ+PT versus WT CTRL (C), shTFEB NZ+PT versus shTFEB CTRL (D; n=2 tumors/group).



Supplemental Figure S12. Tumor growth in immunocompetent versus immunodeficient mice. (A) 1×10^{6} NCI- H2228 wild-type (WT) and TFEB-silenced (shTFEB) cells were injected subcutaneously in female NOD SCID- γ (NSG) mice. When tumors reached the volume of 50 mm³, animals (n=5/group) were randomized and treated for 3 weeks as it follows: 1) control (CTRL) group, treated with 0.1 ml saline solution intravenously (i.v.), once a week; 2) cisplatin (PT) group, treated with 2 mg/kg cisplatin i.v., once a week; 3) NZ, treated with 1 mg/kg NZ i.v., once a week; 4) NZ+PT group, receiving both drugs i.v., once a week simultaneously. Animals were euthanized on day 28 after randomization with zolazepam (0.2 mL/kg) and xylazine (16mg/kg). Data are means±SD. ***p<0.0001: shTFEB versus WT tumors; °°p<0.01: NZ+PT versus CTRL group. (B) Reduction of volume for tumors implanted in Hu-CD34⁺ mice (Figure 6A) and NSG mice (panel A). The mean volume in the CTRL group was considered as 100%. The volumes in the other treatment groups were expressed as percentage versus CTRL group. Data are means±SD. ***p<0.001: treatment groups versus CTRL; °p<0.05, °°°p<0.001: NZ+PT versus PT; #p<0.05; shTFEB versus WT tumors.